Board Committees

Cathy Steiner is a Principal of Origin Merchant Partners having over 20 years of experience as an investment banker, capital markets advisor, and CFO, working closely with healthcare and growth companies on successful financings and strategic transactions. Ms. Steiner was previously CFO for technology companies through capital raising and M&A transactions. For over a decade prior to that, Ms. Steiner was Managing Director for Nucleus GC, a boutique healthcare advisory firm working with numerous clients on financings and strategic transactions, as well as product development, commercialization, positioning and launch. For nearly ten years prior to that, Ms. Steiner led Healthcare Investment Banking for CIBC World Markets and Yorkton Securities. Ms. Steiner has significant experience in dealings with public and private healthcare companies at all stages of development, and across all subsectors including pharmaceutical, medical device, healthcare information technology, drug development and healthcare services. Ms. Steiner holds a MBA from the Schulich School of Business at York University and a MSc in Immunology from McMaster University. She has a CPA, CA designation, earned while working at Deloitte, and contributes to her field as a volunteer advisor for the healthcare practice at MaRS Discovery District in Toronto and as an occasional lecturer for the Chartered Professional Accountants of Ontario.

As Governance/Nominating Committee Chair on Titan Medical’s board of directors, Mr. Giovinazzo drives continuous improvement of the Company’s governance practices. Mr. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases.

He is a co-inventor of the recent FDA approved drug Kynmobi, developed by Cynapsus Therapeutics Inc. (Nasdaq: CYNA) where Mr. Giovinazzo was also CEO and a director until Cynapsus was acquired in an industry leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Mr. Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Mr. Giovinazzo has a Chartered Director (C.Dir.) and Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University and an MBA from IMD Geneva, Switzerland.

Dr. Dan O’Brien, MD, MBA, PhD is an award-winning scientific and academic leader as a physician with a passion and experience for improving patient outcomes through advanced healthcare technologies. 

Dr. O’Brien understands the need to improve quality of care, cost, and access in healthcare. As a former Chief Medical Officer for multiple startups he brings substantial experience in precision medicine, robotic technology, molecular diagnostics, medical device, pharmaceutical and healthcare management. He has worked with several healthcare companies including completing successful startup exits to increase awareness, education, and research in many therapeutic areas.

He has an extensive physician network including relationships with leading medical experts around the world. He has an MD and completed his clinical rotations at Emory University, has a certificate of participation from Johns Hopkins School of Medicine. He has an MBA in healthcare management, PhD in Public health, and a B.A from the University of Notre Dame

Mr. Vance has over 25 years of extensive leadership experience with commercial and operational expertise in the healthcare industry. He is currently the Chairman, President and Chief Executive Officer of PhotoniCare, Inc., and serves as a non-executive member of the Board of Directors of AVITA Medical (NASDAQ: RCEL, ASX:AVH). He has served as a member of Titan Medical’s Board of Directors since September 2020, and was President and CEO of Titan Medical from July 2022 to May 2023. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance currently serves on several AdvaMed Board committees, is NACD Directorship Certified, and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University. 

_{* Reliance on the exemption outlined in section 3.6 of National Instrument 52-110, Audit Committees}

Mr. Vance has over 25 years of extensive leadership experience with commercial and operational expertise in the healthcare industry. He is currently the Chairman, President and Chief Executive Officer of PhotoniCare, Inc., and serves as a non-executive member of the Board of Directors of AVITA Medical (NASDAQ: RCEL, ASX:AVH). He has served as a member of Titan Medical’s Board of Directors since September 2020, and was President and CEO of Titan Medical from July 2022 to May 2023. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance currently serves on several AdvaMed Board committees, is NACD Directorship Certified, and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University. 

_{* Reliance on the exemption outlined in section 3.6 of National Instrument 52-110, Audit Committees}

As Governance/Nominating Committee Chair on Titan Medical’s board of directors, Mr. Giovinazzo drives continuous improvement of the Company’s governance practices. Mr. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases.

He is a co-inventor of the recent FDA approved drug Kynmobi, developed by Cynapsus Therapeutics Inc. (Nasdaq: CYNA) where Mr. Giovinazzo was also CEO and a director until Cynapsus was acquired in an industry leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Mr. Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Mr. Giovinazzo has a Chartered Director (C.Dir.) and Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University and an MBA from IMD Geneva, Switzerland.

Cathy Steiner is a Principal of Origin Merchant Partners having over 20 years of experience as an investment banker, capital markets advisor, and CFO, working closely with healthcare and growth companies on successful financings and strategic transactions. Ms. Steiner was previously CFO for technology companies through capital raising and M&A transactions. For over a decade prior to that, Ms. Steiner was Managing Director for Nucleus GC, a boutique healthcare advisory firm working with numerous clients on financings and strategic transactions, as well as product development, commercialization, positioning and launch. For nearly ten years prior to that, Ms. Steiner led Healthcare Investment Banking for CIBC World Markets and Yorkton Securities. Ms. Steiner has significant experience in dealings with public and private healthcare companies at all stages of development, and across all subsectors including pharmaceutical, medical device, healthcare information technology, drug development and healthcare services. Ms. Steiner holds a MBA from the Schulich School of Business at York University and a MSc in Immunology from McMaster University. She has a CPA, CA designation, earned while working at Deloitte, and contributes to her field as a volunteer advisor for the healthcare practice at MaRS Discovery District in Toronto and as an occasional lecturer for the Chartered Professional Accountants of Ontario.

As Governance/Nominating Committee Chair on Titan Medical’s board of directors, Mr. Giovinazzo drives continuous improvement of the Company’s governance practices. Mr. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases.

He is a co-inventor of the recent FDA approved drug Kynmobi, developed by Cynapsus Therapeutics Inc. (Nasdaq: CYNA) where Mr. Giovinazzo was also CEO and a director until Cynapsus was acquired in an industry leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Mr. Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Mr. Giovinazzo has a Chartered Director (C.Dir.) and Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University and an MBA from IMD Geneva, Switzerland.

Cathy Steiner is a Principal of Origin Merchant Partners having over 20 years of experience as an investment banker, capital markets advisor, and CFO, working closely with healthcare and growth companies on successful financings and strategic transactions. Ms. Steiner was previously CFO for technology companies through capital raising and M&A transactions. For over a decade prior to that, Ms. Steiner was Managing Director for Nucleus GC, a boutique healthcare advisory firm working with numerous clients on financings and strategic transactions, as well as product development, commercialization, positioning and launch. For nearly ten years prior to that, Ms. Steiner led Healthcare Investment Banking for CIBC World Markets and Yorkton Securities. Ms. Steiner has significant experience in dealings with public and private healthcare companies at all stages of development, and across all subsectors including pharmaceutical, medical device, healthcare information technology, drug development and healthcare services. Ms. Steiner holds a MBA from the Schulich School of Business at York University and a MSc in Immunology from McMaster University. She has a CPA, CA designation, earned while working at Deloitte, and contributes to her field as a volunteer advisor for the healthcare practice at MaRS Discovery District in Toronto and as an occasional lecturer for the Chartered Professional Accountants of Ontario.

Mr. Vance has over 25 years of extensive leadership experience with commercial and operational expertise in the healthcare industry. He is currently the Chairman, President and Chief Executive Officer of PhotoniCare, Inc., and serves as a non-executive member of the Board of Directors of AVITA Medical (NASDAQ: RCEL, ASX:AVH). He has served as a member of Titan Medical’s Board of Directors since September 2020, and was President and CEO of Titan Medical from July 2022 to May 2023. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical. Prior to his role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien, and GE HealthCare. Mr. Vance currently serves on several AdvaMed Board committees, is NACD Directorship Certified, and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University. 

_{* Reliance on the exemption outlined in section 3.6 of National Instrument 52-110, Audit Committees}